Figure 3 | Laboratory Investigation

Figure 3

From: Role of amino acid transporter LAT2 in the activation of mTORC1 pathway and the pathogenesis of crescentic glomerulonephritis

Figure 3

Mammalian target of rapamycin complex 1 (mTORC1) activation in crescentic glomerulonephritis (CGN). (a) Immunohistochemistry of phosphorylated forms of S6 ribosomal protein (P-S6 ribosomal protein) and periodic acid-Schiff (PAS) staining by using serial sections. Arrow, arrowhead and asterisk indicate parietal epithelial cells (PECs), podocytes and cellular crescents, respectively. Scale bar=10 μm. (b) Effects of early and late treatment with everolimus on crescentic glomerulonephritis (CGN). CGN was induced in rats by injection of anti-glomerular basement membrane (GBM) antibody on day 0 and daily treatments with everolimus (2.5 mg/kg body weight) or vehicle solution were started either on day 0 (early treatment) or on day 7 (late treatment). Effects of early or late treatment on the glomerular morphology and histology showing cellular crescents and fibrinoid sclerosis. Lower panels were glomeruli enlarged from * of upper panels. Histogram shows summary of renal injury analysis presented as ratio of glomerular cellular crescent, glomerular fibrinoid necrosis and glomeruli without extracapillary lesions.

Back to article page